Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- Nov 9 2018 Adamis Pharmaceuticals Announces Third Quarter 2018 Financial Results and Business Update
- Sep 27 2018 Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
- Aug 27 2018 Adamis Pharmaceuticals Provides Business Update
- Aug 10 2018 Adamis Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update
- Aug 6 2018 Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full